Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is to stimulate hair growth through the alleviation of inflammation at sites of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed for AA; however, tolerability issues, side effects, and the modest efficacy of these treatments underscore the substantial unmet clinical need in AA. The AA pipeline is active, consisting primarily of targeted immunomodulatory agents, and boasts several marketed and investigational JAK inhibitors (e.g., Eli Lilly’s Olumiant, Pfizer’s ritlecitinib, Concert’s CTP-543). This report provides an analysis of AA epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging AA therapies.

QUESTIONS ANSWERED

  • How large is the diagnosed AA population, and how will its size change between 2019 and 2029? How large are the diagnosed alopecia totalis and universalis populations?
  • What are the key unmet clinical needs in AA, and to what degree will they be fulfilled by 2029?
  • What is the current state of treatment in AA, and how will it evolve over time?
  • What emerging AA therapies are viewed by treating dermatologists as most promising, and what sales/uptake will they achieve in AA? How will JAK inhibitors fit into the AA treatment algorithm?

CONTENT HIGHLIGHTS

  • Geographies: United States and EU5.
  • Primary research: Six country-specific interviews with thought-leading dermatologists supported by survey data collected for this study.
  • Epidemiology: Diagnosed and drug-treated prevalence of AA by country.
  • Forecast: Drug-level sales and patient share of key AA therapies in 2029.
  • Emerging therapies:
    • Phase II/III: 4 drugs.
    • Phase II: 4 drugs.
    • Coverage of select preclinical and Phase I products.

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Alopecia - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Alopecia Key Findings
      • Commercial Outlook
        • Key Findings
          • Regional Sales of Key Therapies to Treat Alopecia: 2019 and 2029
          • Alopecia Areata SWOT Analysis
        • Drivers and Constraints
          • What Factors Are Driving Sales in Alopecia Areata?
          • What Factors Are Constraining Sales in Alopecia Areata?
        • Drug-Class-Specific Trends
          • JAK Inhibitors
        • Alternative Market Scenarios
          • Alternative Market Scenarios
          • Alternative Scenarios for the Alopecia Market Through 2029
      • Forecast
        • Sales of Key Therapies in Alopecia
      • Etiology and Pathophysiology
        • Disease Overview
          • Key Genetic Susceptibility Loci in Alopecia Areata
            • Key Pathways and Drug Targets
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incidence of Alopecia Areata
                  • Diagnosed Incident Cases of Alopecia in the Major Pharmaceutical Markets: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incidence of Alopecia Areata by Severity
                  • Diagnosed Incident Cases of Alopecia by Severity in the Major Pharmaceutical Markets: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Lifetime Prevalence of Alopecia Areata
                  • Diagnosed Lifetime Prevalent Cases of Alopecia Areata in the Major Pharmaceutical Markets: 2019-2029
                  • Drug-Treated Prevalent Cases of Alopecia Areata: 2019-2029
              • Current Treatment
                • Key Findings
                  • Diagnosis
                    • Treatment Providers and Referral Patterns
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Alopecia
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Alopecia Areata
                    • Current Treatments Used for Alopecia Areata
                    • Market Events Impacting the Use of Key Current Therapies in Alopecia Areata
                    • Nonsteroidal Topical Agents
                    • Clinical Trial Outcomes for Nonsteroidal Topical Agents
                    • Advantages and Disadvantages of Nonsteroidal Topical Agents
                    • Expert Insight: Nonsteroidal Topical Agents
                    • Corticosteroids
                    • Clinical Trial Outcomes for Corticosteroids
                    • Advantages and Disadvantages of Corticosteroids
                    • Expert Insight: Corticosteroids
                    • Contact Allergens
                    • Clinical Trial Outcomes for Contact Allergens
                    • Advantages and Disadvantages of Contact Allergens
                    • Expert Insight: Contact Allergens
                    • Conventional Immunosuppressants
                    • Clinical Trial Outcomes for Conventional Immunosuppressants
                    • Advantages and Disadvantages of Conventional Immunosuppressants
                    • Expert Insight: Conventional Immunosuppressants
                    • JAK Inhibitors
                    • Clinical Trial Outcomes for JAK Inhibitors
                    • Advantages and Disadvantages of JAK Inhibitors
                    • Key Results from Select Clinical Trials Investigating JAK Inhibitors for the Treatment of Alopecia Areata
                    • Ongoing Clinical Development of JAK Inhibitors
                    • Expert Insight: JAK Inhibitors
                  • Medical Practice
                    • Overview
                    • Treatment Guidelines
                    • Country and/or Regional Alopecia Areata Treatment Guidelines
                    • Generalized Treatment Decision Tree for Alopecia Areata
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Alopecia Areata
                  • Top Unmet Needs in Alopecia Areata: Current and Future Attainment
                  • Expert Insight: Unmet Need in Alopecia Areata
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends for Alopecia Areata
                  • Key Emerging Therapies
                    • Notable Developments Among Key Emerging Therapies for Alopecia Areata
                    • Key Therapies in Development for Alopecia Areata
                    • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Alopecia Areata
                    • CTP-543 Profile
                    • Key Ongoing Clinical Trials of CTP-543 in the Treatment of Alopecia Areata
                    • Analysis of the Clinical Development Program for CTP-543
                    • Expert Insight: CTP-543
                    • Expectations for Launch and Sales Opportunity of CTP-543 in Alopecia Areata
                    • Olumiant Profile
                    • Key Ongoing Clinical Trials of Olumiant in the Treatment of Alopecia Areata
                    • Analysis of the Clinical Development Program for Alopecia
                    • Expert Insight: Olumiant
                    • Expectations for Launch and Sales Opportunity of Olumiant in Alopecia Areata
                    • Ritlecitinib Profile
                    • Key Ongoing Clinical Trials of Ritlecitinib in the Treatment of Alopecia Areata
                    • Analysis of the Clinical Development Program for Ritlecitinib
                    • Expert Insight: Ritlecitinib
                    • Expectations for Launch and Sales Opportunity of Ritlecitinib in Alopecia Areata
                    • Brepocitinib Profile
                    • Analysis of the Clinical Development Program for Brepocitinib
                    • Expert Insight: Brepocitinib
                    • Expectations for Launch and Sales Opportunity of Brepocitinib in Alopecia Areata
                  • Early-Phase Pipeline Analysis
                    • Notable Developments in the Early-Phase Pipeline for Alopecia Areata
                    • Select Compounds in Early-Phase Development for Alopecia Areata
                  • Key Discontinuations and Failures in Alopecia
                    • Key Discontinuations and Failures
                  • Patient Registries
                    • Patient Registries for Alopecia
                • Access & Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Alopecia Areata: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Alopecia Areata: EU5
                    • General Reimbursement Environment: EU5
                • Methodology
                  • Bottom-Up Forecasting Overview
                    • Patient Populations
                    • Drug-Specific Assumptions
                  • Bottom-Up Forecast Assumptions
                    • General Sources of Data
                    • Drug-Treatment Rate Assumptions in Alopecia Areata
                    • Patient-Share Assumptions in Alopecia
                    • General Statements About Pricing
                    • Sources for Drug Prices
                    • 2019 Exchange Rates
                    • Price per Treated Day: 2029
                    • Dosing, Days of Therapy, and Compliance
                    • Out-Year Forecasting
                    • Emerging Therapy Prices
                  • Primary Market Research
                    • Experts Interviewed
                • Appendix
                  • Key Abbreviations Related to Alopecia Areata
                  • Brands, Marketers, and Generic Availability of Key Therapies for Alopecia Areata, by Market
                  • Alopecia Areata Bibliography

              Author(s): Sonal Divekar; Stephanie Niquita

              Sonal Divekar is an analyst on DRG’s Infectious, Niche & Rare Diseases team, covering diverse indications across the niche & rare portfolio. Prior to this role, she was working as a Senior Analyst at Merck’s Global Centre for Analytics and Forecasting. Her role focused on creating Long Range Forecasts and Demand Forecasts for therapeutic areas like Diabetes and Immunology for the European market. She holds a Master’s degree in Marketing Management from Symbiosis Institute of Business Management, India and a Master’s degree in Microbiology from Pune University, India.

              Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.